Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Downregulation of p53 by MDM2-mediated proteasomal degradation makes cells resistant to apoptosis. The MDM2-p53 interaction is well characterized, but the mechanisms that regulate the interaction are not well understood. Here, we show that PA28gamma, a proteasome activator that inhibits apoptosis and promotes cell cycle progression through unknown mechanisms, exerts an effect as a cofactor in the MDM2-p53 interaction. The polymer form of PA28gamma interacts with both MDM2 and p53 proteins and facilitates their physical interaction. This promotes ubiquitination- and MDM2-dependent proteasomal degradation of p53, limiting its accumulation and resulting in inhibited apoptosis after DNA damage. Elimination of endogenous PA28gamma in human cancer cells abrogates MDM2-mediated p53 degradation, increases the activity of p53, and enhances apoptosis. These findings reveal the mechanism by which PA28gamma affects apoptosis and proliferation. Manipulation of the level of PA28gamma, an approach that would regulate the cellular content of p53, may improve the efficacy of current cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · cited 1×
“Tumor suppressor p53 is involved in controlling cell growth and differentiation and in the maintenance of genomic in- tegrity, with high levels of p53 activity inducing apoptosis, cell cycle arrest, or senescence (Lane, 1992).”
BackgroundMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 3×
“In unstressed cells, the level of p53 (hence its activity) is largely controlled by MDM2, an oncoprotein containing an ubiquitin E3 ligase (Haupt et al, 1997; Brooks and Gu, 2006).”
BackgroundZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“Several regulators of the MDM2–p53 interaction have been identified, including p14Arf (Pomerantz et al, 1998; Zhang et al, 1998a), YY1 (Sui et al, 2004), MDMX (Francoz et al, 2006), gankyrin (Higashitsuji et al, 2005), L11 (Lohrum et al, 2003), and Daxx (Tang et al, 2006).”
BackgroundRescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 2×
“MDM2 knockout results in lethality early in development in mice (Jones et al, 1995; Montes de Oca Luna et al, 1995).”
BackgroundRescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · cited 1×
“MDM2 is considered a target for human cancer therapy (Bond et al, 2004; Zhang et al, 2005; Poyurovsky and Prives, 2006).”
Backgroundp53 ubiquitination: Mdm2 and beyond
Brooks, C. L., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.020 · Cited by 924
Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2
Li, M., Brooks, C. L., Wu-Baer, F., Chen, D., Baer, R., & Gu, W. (2003) · Science · doi:10.1126/science.1091362 · Cited by 804 · cited 4×
“We utilized a previously described protocol to evaluate ubiquitination (Li et al, 2003).”
BackgroundMethodInfluential
Cited by
The proteasome: overview of structure and functions
TANAKA, K. (2009) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.85.12 · Cited by 862
The MDM2-p53 pathway revisited
Subhasree, N., Jiangjiang, Q., Kalkunte, S., Minghai, W., & Ruiwen, Z. (2013) · The Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414
RNF4, a SUMO-targeted ubiquitin E3 ligase, promotes DNA double-strand break repair
Galanty, Y., Belotserkovskaya, R., Coates, J., & Jackson, S. P. (2012) · Genes & Development · doi:10.1101/gad.188284.112 · Cited by 314
“These included the proteasome activator PSME3, implicated in MDM2-mediated p53 degradation (Zhang and Zhang 2008) and recently in the DDR (Levy-Barda et al. 2011); PSMD7, a core component of the 19S proteasome regulator (PA700); the peptidase PSMA3, a core component of the proteolytic 20S…”
BackgroundLi, J., Feng, X., Sun, C., Zeng, X., Xie, L., Xu, H., Li, T., Wang, R., Xu, X., Zhou, X., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.07.004 · Cited by 38
Metadata
- Authors
- Zhang, Z., & Zhang, R.
- Venue
- The EMBO Journal
- Published
- 2008-02-28
- Volume
- 27
- Issue
- 6
- Pages
- 852-864
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- OpenAlex
- W1966805549
- Cited by
- 153
- References
- 13
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation. https://app.cochat.ai/papers/10.1038/emboj.2008.25
- The paper
- Zhang, Z., & Zhang, R. (2008). Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation. The EMBO Journal. https://doi.org/10.1038/emboj.2008.25
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.